Inspiration Healthcare Group

IHC · AIM · Health Care · mcap £17m · 18.5p

Inspiration Healthcare designs and distributes medical devices for neonatal and respiratory care, including its own SLE ventilators, plus third-party products. It sells mainly to health services in the UK and export markets.

Target	Promise	Said	Status
2025
FY25	FY25 revenues to be second-half weighted	2 Oct 2024	✓ Kept
	“we expect revenues for FY25 to be H2 weighted” Result H2 FY25 revenue £21.3m versus H1 £17.0m; full year £38.3m. “Strong H2 revenue of £21.3 million (H1: £17.0 million) and full year revenue of £38.3 million”18 Feb 2025 · Trading update
2026
H1 FY26	Deliver $6m humanitarian contract in H1 FY26	18 Feb 2025	✓ Kept
	“Delivery of this contract is anticipated to be in the first half of this financial year.” Result H1 FY26 revenue rose 41% to £24.0m, with the $6m contract cited. “$6 million humanitarian aid contract fully delivered in the period”20 Aug 2025 · Trading update and notice of results “We also delivered the $6 million order with UNICEF for SLE6000 and SLE1500 ventilators and accessories in full in the period.”7 Oct 2025 · Half-year Results
early FY26	Recognise about $2m Middle East contract revenue in early FY26	18 Feb 2025	✓ Kept
	“The revenue from this initial shipment of circa $2 million is expected to be recognised in early FY26 on receipt of the goods by the customer” Result H1 FY26 results cite two major export contracts; second shipment due H2 FY26. “The first shipment of the delayed Middle East order was delivered to the customer during H1 and payment received. We are awaiting issue of the letter of credit for the second and final shipment and this is expected to be delivered in H2.”7 Oct 2025 · Half-year Results
FY26	Deliver strong first half and meet full-year market expectations in FY26	24 Jul 2025	✓ Kept
	“We remain confident in delivering our full-year expectations and creating long-term value for shareholders.” Also stated 20 Aug 2025 Result H1 revenue ahead of expectations; FY26 revenue £47.5m, slightly ahead of consensus, EBITDA in line. “Revenue for the year increased by approximately 24% to £47.5 million (FY25: £38.3 million), slightly ahead of consensus market expectations, following a strong H2 performance across the Group. Adjusted EBITDA is expected to be in line with market consensus”12 Feb 2026 · Full year trading update